The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail


20 milligram(s) Capsule, hard

Celgene Europe B.V.EU/1/07/391/009

Main Information

Trade NameRevlimid
Active SubstancesLenalidomide
Strength20 milligram(s)
Dosage FormCapsule, hard
Licence HolderCelgene Europe B.V.
Licence NumberEU/1/07/391/009

Group Information

ATC CodeL04AX Other immunosuppressants
L04AX04 lenalidomide


Licence Issued19/02/2015
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back